Investment
Features
FeesSafety
Academy
More
Pluang+

Buckle posts strong Q2 with EPS $0.87 and revenue $319.82M, beating estimates despite slight net income dip.

Company Fundamentals
21 Aug 2026
Gordon Thompson
View Source
Bullish
pluang ai news

Buckle, Inc. reported strong Q2 earnings with an EPS of $0.87, surpassing analyst estimates of $0.81, and revenue of $319.82 million, slightly above expectations. The company saw a 4.6% increase in net sales, driven by growth in both comparable-store and online sales. Despite a small decline in net income due to higher expenses, Buckle improved its gross margin to 47.8%, indicating solid profitability. The company maintains strong liquidity with a current ratio of 2.04, positioning it well for future growth in the competitive apparel market.

More News

IM Cannabis to execute 1-for-30 reverse stock split to meet Nasdaq's $1 minimum share price

IM Cannabis to execute 1-for-30 reverse stock split to meet Nasdaq's $1 minimum share price

IM Cannabis Corp., a medical cannabis company operating in Israel and Germany, will conduct a 1-for-30 reverse stock split on August 27, 2026. This move aims to increase its share price, currently at $0.11, to meet the Nasdaq Capital Market's minimum...

Company Fundamentals
Neutral
1 hour ago
KE Holdings beats EPS estimates with strong profit despite revenue drop in Q2 2026

KE Holdings beats EPS estimates with strong profit despite revenue drop in Q2 2026

KE Holdings Inc. reported Q2 2026 earnings with an EPS of $0.42, surpassing the $0.31 consensus estimate. Although revenue declined 5.7% year-over-year to about $3.60 billion, the company doubled its net income thanks to effective cost controls and o...

Company Fundamentals
Bullish
2 hours ago
Structure Therapeutics' oral GLP-1 drug shows 16.2% weight loss, advancing to Phase 3 with strong cash backing.

Structure Therapeutics' oral GLP-1 drug shows 16.2% weight loss, advancing to Phase 3 with strong cash backing.

Structure Therapeutics (GPCR) maintains a Buy rating after its oral GLP-1 drug aleniglipron showed up to 16.2% weight loss in Phase 2b trials targeting obesity. The drug demonstrated a favorable safety profile and is now in Phase 3, with pivotal data...

Analyst Insights
Bullish
4 hours ago
Lawsuit filed against Aevex over misleading IPO lock-up waiver disclosures causing stock drop

Lawsuit filed against Aevex over misleading IPO lock-up waiver disclosures causing stock drop

Scott+Scott Attorneys at Law has filed a securities class action lawsuit against Aevex Corp., its directors, officers, and IPO underwriters. The suit alleges that they made false and misleading statements about a pre-arranged plan to waive the 180-da...

Market News
Bearish
4 hours ago
Synopsys beats earnings, raises guidance, and outpaces Cadence ahead of Q3 report.

Synopsys beats earnings, raises guidance, and outpaces Cadence ahead of Q3 report.

Synopsys reported strong Q2 results with a 5.96% EPS beat and 42% revenue growth, raising its full-year 2026 guidance. The company benefits from growing AI-driven demand in semiconductor design automation, expanding margins, and significant debt redu...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App